Sjogren’s is tough to study, isn’t it? LOUiSSe (remibrutinib proof-of-concept SjS) - benefit with: - ESSDAI (primary, obj dx activity) ✅ - auto-Ab ✅ - all patient outcomes ❎ Has already exceeded many attempts Even then, still some limitations ABST1113 #ACR22 @RheumNow https://t.co/NlBaFVuuPa